Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Bone Marrow Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm
Bone Marrow Neoplasm

Cancer Family

Bone Marrow Neoplasm

CI-CAN-00000093Explore in graph →

Non-malignant1,034 active trials28 approved drugs633 evidence items

NCIt: C35370
MeSH: D019046

Overview
Statistics
Survival
Genomics18
Variants & evidence633
Drugs53
Trials4612
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (219)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 201–219 of 219 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
· Exp Hematol · 2014 · PMID 24333121 · validated civic_curation pubmed
Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
· Leuk Res · 2008 · PMID 18191450 · validated civic_curation pubmed
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
· Blood · 2006 · PMID 16772610 · validated civic_curation pubmed
Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.
· Blood · 2004 · PMID 15256420 · validated civic_curation pubmed
Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
· Blood · 2004 · PMID 15304385 · validated civic_curation pubmed
AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.
· Leukemia · 2007 · PMID 17330097 · validated civic_curation pubmed
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.
· Proc Natl Acad Sci U S A · 2005 · PMID 15705718 · validated civic_curation

Showing 201–219 of 219 publications

← Previous
1
…
8
9
Next →

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.

· Mol Cancer Ther · 2018 · PMID 29237803 · validated civic_curation pubmed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

· Blood · 2004 · PMID 15178581 · validated civic_curation pubmed

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

· Blood · 2017 · PMID 27908881 · validated civic_curation pubmed

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

· Nat Commun · 2019 · PMID 31784538 · validated civic_curation pubmed

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

· Cancer Cell · 2007 · PMID 18068628 · validated civic_curation pubmed

Extreme mutational selectivity of axitinib limits its potential use as a targeted therapeutic for BCR-ABL1-positive leukemia.

· Leukemia · 2016 · PMID 26582647 · validated civic_curation pubmed

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia.

· Blood Cancer J · 2014 · PMID 24927407 · validated civic_curation pubmed

Tyner et al. Nature 2018

· 2018 · PMID 30333627 · validated cbioportal_study pubmed

Bottomly et al. Cancer Cell 2022

· 2022 · PMID 35868306 · validated cbioportal_study pubmed

TCGA, NEJM 2013

· 2013 · PMID 23634996 · validated cbioportal_study pubmed

Yoshida et al. Nature 2011

· 2011 · PMID 21909114 · validated cbioportal_study pubmed

Nangalia et al. NEJM 2013

· 2013 · PMID 24325359 · validated cbioportal_study pubmed